Endocrine-Metabolic Function in Remission-Phase IDDM During Administration of Cyclosporine

@article{Dupr1991EndocrineMetabolicFI,
  title={Endocrine-Metabolic Function in Remission-Phase IDDM During Administration of Cyclosporine},
  author={J. Dupr{\'e} and M. Jenner and J. Mahon and C. Purdon and N. Rodger and C. Stiller},
  journal={Diabetes},
  year={1991},
  volume={40},
  pages={598 - 604}
}
We have studied the endocrine-metabolic status of patients in non–insulin-receiving (NIR) remission of insulin-dependent diabetes mellitus (IDDM) within 6–60 mo of diagnosis during administration of cyclosporine, in comparison with nondiabetic subjects. IDDM patients in NIR remission were recognized when target glycemic control (plasma glucose and mean capillary blood glucose levels <7.8 mM before meals) was maintained without administration of insulin for at least 2 wk. In so-called… Expand
Glycaemic effects of incretins in Type 1 diabetes mellitus A concise review, with emphasis on studies in humans
TLDR
The capacity of this combination therapy to normalize blood glucose levels after ingestion of meals that were consistent with the dietary program of the volunteers, without apparent increased risk of hypoglycaemia within a normal between-meals interval is demonstrated. Expand
Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose.
TLDR
These data characterize a novel group of subjects with type 1 diabetes manifested solely by hyperglycemia following an oral glucose load in whom islet function is normal at euglycemia, but who have marked defects in both alpha- and beta-cell secretion at hyper glycemia. Expand
Differential β-cell response to glucose, glucagon, and arginine during progression to type I (insulin-dependent) diabetes mellitus
TLDR
Whereas AIRG deteriorates during prediabetes, AIRArg appears to be less altered with time and increased basal glycemia, remaining substantial even at the onset of the disease. Expand
The case for intravenous arginine stimulation in lieu of mixed-meal tolerance tests as outcome measure for intervention studies in recent-onset type 1 diabetes.
TLDR
The goal was to determine whether arginine-stimulated C-peptide could be used in lieu of MMTT as an outcome measure for intervention studies in recent-onset type 1 diabetes. Expand
Glucagon-like peptide 1 improved glycemic control in type 1 diabetes
TLDR
It is demonstrated that subcutaneous GLP-1 can improve glucose control in type 1 diabetes without adverse effects when self-administered before meals with usual insulin during established intensive insulin treatment programs. Expand
Small Doses of Subcutaneous Insulin as a Strategy for Preventing Slowly Progressive β-Cell Failure in Islet Cell Antibody—Positive Patients With Clinical Features of NIDDM
TLDR
Subcutaneous small doses of insulin, resulting in a high rate of negative conversion of ICA and an improved serum C-peptide response, may be effective in treating ICA+ NIDDM patients who are at high risk for slowly progressive β-cell failure. Expand
Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes.
TLDR
Normalization of postcibal glycemia was associated with delayed gastric emptying and suppression of glucagon secretion, without increased secretion or blood levels of insulin, suggesting that tGLP-1 agonists have therapeutic potential as congeners with insulin in C-peptide-negative type 1 diabetes. Expand
Intervention and Prevention Strategies
Insulin-dependent diabetes mellitus (IDDM), or type 1 diabetes, is the outcome of a progressive and selective destruction of the insulin-producing beta cells in the islets of Langerhans in theExpand
Function of Isolated Pancreatic Islets From Patients at Onset of Type 1 Diabetes: Insulin Secretion Can Be Restored After Some Days in a Nondiabetogenic Environment In Vitro
TLDR
The insulin secretion ability by in vitro glucose perifusion and the expression of insulin pathway genes in isolated islets of Langerhans from these patients indicate that the potential for endogenous insulin production is good, which could be taken advantage of if the disease process was reversed at diagnosis. Expand
Left ventricular diastolic function in hypertension and role of plasma glucose and insulin. Comparison with diabetic heart.
TLDR
Hypertension is associated with increased diastolic stiffness of the left ventricle, which is enhanced by moderate obesity, and abnormal carbohydrate metabolism, and a large rise in stiffness suggests a potential role for growth factors in further alteration of myocardial composition. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 16 REFERENCES
Cyclosporin-Induced Remission of IDDM After Early Intervention: Association of 1 yr of Cyclosporin Treatment With Enhanced Insulin Secretion
  • Medicine
  • Diabetes
  • 1988
TLDR
Results show that cyclosporin treatment initiated soon after diagnosis increases the rate of remission and enhances β-cell function during the 1st yr of IDDM, and it is concluded that a continuing search for clinically beneficial immunomodulatory therapies designed to prevent or ameliorate the disease is feasible and worthwhile. Expand
Intravenous Glucose Tolerance and Pancreatic Islet β-Cell Function in Patients With Multiple Sclerosis During 2-yr Treatment With Cyclosporin
TLDR
It appears that cyclosporin can be given in conventional doses for as long as 2 yr without encountering evidence for impaired glucose homeostasis, however, whether adverse effects will materialize over longer periods of drug use remains a question. Expand
Immunoreactive gastric inhibitory polypeptide response to a meal during the first eighteen months after diagnosis of type 1 (insulin dependent) diabetes mellitus.
TLDR
No causal relationship between the changes in beta- cell function and IR-GIP during the first 18 months after the onset of the disease seems to exist, and Lack of endogenous GIP therefore does not explain the diminished beta-cell function in Type 1 diabetes a few months after onset ofThe disease. Expand
Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset.
TLDR
A pilot study in which 41 patients were treated with the immunosuppressive agent cyclosporine for 2 to 12 months indicates that a controlled trial of the effects of cyclospora in type I diabetes should be conducted. Expand
Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus.
TLDR
In the presence of a plasma glucose concentration of 8 mmol/L, physiologic concentrations of porcine GIP caused an immediate but impaired beta-cell response in IDD and NIDD patients. Expand
Reduction of Glycemic Potentiation: Sensitive Indicator of β-Cell Loss in Partially Pancreatectomized Dogs
TLDR
A reduction in glycemic potentiation of the insulin response to arginine was found to be the best means of detecting the subclinical β-cell loss induced by a two-thirds PX in dogs. Expand
CYCLOSPORIN INCREASES THE RATE AND LENGTH OF REMISSIONS IN INSULIN-DEPENDENT DIABETES OF RECENT ONSET Results of a Multicentre Double-blind Trial
TLDR
It is indicated that cyclosporin promotes the remission of type I diabetes and the need for new controlled protocols aimed at evaluating the length of the effect and selecting the best drug regimen is suggested. Expand
Toxic effects of cyclosporine on the endocrine pancreas of Wistar rats.
TLDR
It is concluded that pancreatic beta cells are sensitive to toxic effects of cyclosporine in vivo, and the measurement of glucose tolerance, as a sensitive parameter of a toxic cyclOSporine action, should be included in the monitoring of grafted patients under cyclospora treatment. Expand
Type I diabetes mellitus in monozygotic twins: chronic progressive beta cell dysfunction.
In a prospective 21-year study, islet cell antibodies and beta cell function were serially assessed in 24 monozygotic twins initially discordant for type I diabetes mellitus. Eighteen of 21 twinsExpand
Alimentary factors in the endocrine response to administration of arginine in man.
TLDR
Findings support the suggestion that humoral secretions of the gut are involved in the insulin response to aminoacids, as changes in the blood-levels were not significant during either of the other two infusions, but intraduodenal infusion led to a sustained increase in serum-I.R.I. in contrast to a transient increase when arginine was given intravenously. Expand
...
1
2
...